MABVAX THERAPEUTICS HLDGS INC
MBVX
MBVX was delisted on the 10th of July, 2018.
2 hedge funds and large institutions have $31K invested in MABVAX THERAPEUTICS HLDGS INC in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 0 closing their positions.
3,000% more capital invested
Capital invested by funds: $1K → $31K (+$30K)
100% more funds holding
Funds holding: 1 → 2 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$29K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $29K | +$29K | +582,855 | New |
|
|
PAM
2
Panagora Asset Management
Boston,
Massachusetts
| $2K | – | – | – |
|
MBVX Hedge Fund Activity: Q2 2019 in Review
2 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in MABVAX THERAPEUTICS HLDGS INC (MBVX) for Q2 2019, worth a combined $31K — up 3,000% from $1K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new MBVX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $29K.
- 2 institutional investors held MABVAX THERAPEUTICS HLDGS INC (MBVX) as of Q2 2019, up from 1 in Q1 2019.
- Funds reported $31K of MABVAX THERAPEUTICS HLDGS INC stock for Q2 2019, up 3,000% quarter-over-quarter.
- 1 fund opened new MABVAX THERAPEUTICS HLDGS INC positions in Q2 2019 and 0 closed out, a net change of +1 holder.
- The largest MABVAX THERAPEUTICS HLDGS INC buyer in Q2 2019 was Cambridge Investment Research Advisors, an estimated $29K added.
Based on aggregated 13F filings for Q2 2019.